The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of fixed-dose-rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced bile duct cancer: Daegu Gyeoungbuk Oncology Group.
Hun-Mo Ryoo
Disclosure not yet available
Sung Hwa Bae
Disclosure not yet available
Min Kyoung Kim
Disclosure not yet available
Kyung Hee Lee
Disclosure not yet available
Hong-Suk Song
Disclosure not yet available
Yee Soo Chae
Disclosure not yet available
Won Sik Lee
Disclosure not yet available
Jin Ho Baek
Disclosure not yet available